- Home
- DOMH vs EPIX Comparison
DOMH vs EPIX Comparison
Compare DOMH & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- EPIX
- Stock Information
- Founded
- DOMH 1967
- EPIX 2009
- Country
- DOMH United States
- EPIX Canada
- Employees
- DOMH N/A
- EPIX N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- EPIX Health Care
- Exchange
- DOMH Nasdaq
- EPIX Nasdaq
- Market Cap
- DOMH 74.9M
- EPIX 76.8M
- IPO Year
- DOMH N/A
- EPIX N/A
- Fundamental
- Price
- DOMH $8.20
- EPIX $1.72
- Analyst Decision
- DOMH
- EPIX Hold
- Analyst Count
- DOMH 0
- EPIX 3
- Target Price
- DOMH N/A
- EPIX $2.00
- AVG Volume (30 Days)
- DOMH 4.4M
- EPIX 253.9K
- Earning Date
- DOMH 03-31-2025
- EPIX 02-11-2025
- Dividend Yield
- DOMH N/A
- EPIX N/A
- EPS Growth
- DOMH N/A
- EPIX N/A
- EPS
- DOMH N/A
- EPIX N/A
- Revenue
- DOMH $12,589,000.00
- EPIX N/A
- Revenue This Year
- DOMH N/A
- EPIX N/A
- Revenue Next Year
- DOMH N/A
- EPIX N/A
- P/E Ratio
- DOMH N/A
- EPIX N/A
- Revenue Growth
- DOMH 1117.50
- EPIX N/A
- 52 Week Low
- DOMH $0.83
- EPIX $1.40
- 52 Week High
- DOMH $13.58
- EPIX $9.92
- Technical
- Relative Strength Index (RSI)
- DOMH 58.54
- EPIX 47.93
- Support Level
- DOMH $8.25
- EPIX $1.69
- Resistance Level
- DOMH $12.00
- EPIX $1.83
- Average True Range (ATR)
- DOMH 2.15
- EPIX 0.07
- MACD
- DOMH 0.40
- EPIX 0.01
- Stochastic Oscillator
- DOMH 51.22
- EPIX 57.69
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.